Motley Fool

2 Pharma Stocks With Blockbuster Drugs on the Horizon

AbbVie’s Humira, used to treat inflammatory conditions such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, has been the world’s top-selling drug for years. Now, Eli Lilly (NYSE: LLY) and Bristol Myers Squibb (NYSE: BMY) have blockbuster drugs in the works that could also change lives plus boost their companies’ fortunes. Lilly’s Mounjaro (tirzepatide), an once-weekly injection, received its first Food and Drug Administration (FDA) approval in May as a therapy to treat type 2 diabetes, but the therapy also has huge potential as a weight-loss medication.

Leave a Reply

Your email address will not be published. Required fields are marked *